# OnCo record nct04468984 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04468984/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04468984", "NCT04468984" ;
  schema:name "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis"@en ;
  schema:alternateName "TRANSFORM-2"@en ;
  schema:description "A phase 3 trial testing Navitoclax in myeloproliferative neoplasms, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04468984/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04468984> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-08-31" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/primary-myelofibrosis/> ;
  onco:drugs <https://onco.cc/drugs/navitoclax/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .